公告称，与一家在全国拥有强大开发及商业化能力以及充足临床资源的大型医药公司合作以加快开发标的产品符合集团的最佳利益。此举亦符合行业惯例，并为集团带来商业利益，因为与中美华东的合作有利于标的产品充分拓展多适应症，释放产品价值；加快标的产品现有III期临床试验的开发进度，并为集团带来更多资金支持。In the afternoon, China Quanxing's B (02509) rose nearly 9%. As of the press release, it rose 7.17% and was reported at HKD 24.65, with a turnover of HKD 2.1469 million.
According to the Wise News APP, China Quanxing's B (02509) rose nearly 9% in the afternoon. As of the press release, it rose 7.17% and was reported at HKD 24.65, with a turnover of HKD 2.1469 million.
On the news front, earlier China Quanxing announced a cooperation agreement with huadong medicine's wholly-owned subsidiary Sino-US Huadong on July 19, 2024. Accordingly, the company grants Sino-US Huadong exclusive joint development rights of target products in the authorized region and field; exclusive market promotion selection rights; and priority transfer rights of the listing permit holder.
The announcement stated that partnering with a large pharmaceutical company with strong development and commercialization capabilities and sufficient clinical resources nationwide is in line with the best interests of the group to expedite the development of the target product, which is consistent with industry practices and brings commercial benefits to the group. The cooperation with Zhongmei Huadong will help expand the indications of the target product and unlock its value, accelerate the development progress of the existing phase III clinical trials of the target product, and bring more funding support to the group.
